| NCT ID | NCT07280923 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baylor University |
| Condition | Neurologic Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2025-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is testing the psychometric properties of a new tool to determine recommendations for pressure relief frequency in wheelchair users.
Eligibility Criteria
Inclusion Criteria: * primary wheelchair user * diagnosed with a neurologic disorder Exclusion Criteria: * does not use a wheelchair for more than 50% of waking hours
Contact & Investigator
Elizabeth Ardolino, PT, PhD
PRINCIPAL INVESTIGATOR
Baylor University
Frequently Asked Questions
Who can join the NCT07280923 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neurologic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07280923 currently recruiting?
Yes, NCT07280923 is actively recruiting participants. Contact the research team at antonia_silva@baylor.edu for enrollment information.
Where is the NCT07280923 trial being conducted?
This trial is being conducted at Waco, United States.
Who is sponsoring the NCT07280923 clinical trial?
NCT07280923 is sponsored by Baylor University. The principal investigator is Elizabeth Ardolino, PT, PhD at Baylor University. The trial plans to enroll 15 participants.